Femasys price target raised to $15 from $12 at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on Femasys (FEMY) to $15 from $12 and keeps a Buy rating on the shares after the company announced that it has established a partnership with CNY Fertility, a national provider of fertility services. The firm has updated its model to include outside of the U.S. sales for FemBloc as the company recently announced EU approval of the FemBloc delivery system and also announced two distributor partnerships in Spain, the analyst tells investors, noting that the firm is now modeling global peak annual sales for FemBloc of $1B, though assuming odds of success of 25%, which it calls “conservative.”